Related Experiment Video

Updated: Jan 23, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.6K

Efficacy of Azithromycin in a Mouse Pneumonia Model against Hospital-Acquired Methicillin-Resistant Staphylococcus

Yu Yamashita1, Kentaro Nagaoka2, Hiroki Kimura1

  • 1Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Antimicrobial Agents and Chemotherapy
|June 26, 2019
PubMed

Insights

Azithromycin (AZM) significantly improved survival in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. This macrolide antibiotic demonstrated efficacy in vivo, outperforming other treatments and reducing bacterial load in lungs.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Macrolides are used for pneumonia, but their efficacy against methicillin-resistant Staphylococcus aureus (MRSA) is unclear.
  • MRSA pneumonia poses a significant clinical challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the efficacy of azithromycin (AZM) against MRSA pneumonia in a murine model.
  • To compare AZM's therapeutic effect with vancomycin (VCM) and daptomycin (DAP).

Main Methods:

  • A murine model of MRSA pneumonia was established via intratracheal injection.
  • Mice were treated with AZM, VCM, or DAP, and survival rates were assessed.
  • In vitro studies evaluated AZM's effect on MRSA growth and toxin gene expression.

Main Results:

  • AZM treatment significantly increased survival and reduced lung bacterial counts compared to controls and other drugs.
  • In vitro, AZM inhibited MRSA growth in the late log phase but not the stationary phase.
  • No significant reduction in cytokine or toxin levels was observed with AZM treatment in vivo or in vitro.

Conclusions:

  • Azithromycin demonstrates significant in vivo efficacy against MRSA pneumonia in a murine model, improving survival.
  • The mechanism may involve suppression of early-stage MRSA growth in vivo, despite limited in vitro effects on growth and toxin production.
Keywords:
azithromycinmethicillin-resistant Staphylococcus aureusmurine modelpneumonia

More Related Videos

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.4K
Development and Assessment of Intracellular Infection Models for Staphylococcus aureus08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

1.2K

Related Concept Videos

Hospitals-II00:59

Hospitals-II

Hospitals provide inpatient and outpatient services. Inpatient services provide care to patients that stay in the hospital for an extended period, ranging from days to months. Examples of inpatient services include intensive care units, hospital wards, or surgeries. Outpatient services provide care to patients who come to a hospital for a diagnostic or treatment but do not stay overnight —for example, diagnostic tests, surgical procedures, or health education.
Nurses that work in...
1.1K
Hospitals-I01:28

Hospitals-I

Hospitals offer medical and surgical care to the sick and injured, along with accommodation while they recover. At the same time, they also provide outpatient, emergency, psychiatric, and rehabilitation services to meet various community needs. In addition to providing medical care, hospitals also act as hubs for medical research and training. Hospitals use clinical procedures and evidence-based practice standards to deliver patient care. To deliver safe and efficient care, a nurse must stay up...
1.5K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
778
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.7K
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
210
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
778